Centene Corporation’s Stock Price Plunges to $63.00, Experiencing a Significant 9.09% Drop

Centene Corporation (CNC)

63.00 USD -6.30 (-9.09%) Volume: 14.58M

Centene Corporation’s stock price takes a hit, currently trading at 63.00 USD, a significant drop of -9.09% this trading session. With a high trading volume of 14.58M and a year-to-date percentage change of -15.11%, CNC’s stock performance shows a bearish trend in the market.

Latest developments on Centene Corporation

Centene Corp. experienced a tumultuous day in the stock market as it underperformed compared to its competitors, despite some daily gains. The stock touched a 52-week low at $62.99 amidst market shifts and oversold conditions. However, there was some positive news as Centene’s Meridian unit secured a contract for the HIDE SNP plan in Michigan. On the flip side, both Molina and Centene saw significant drops following a profit warning from Elevance Health. Investor activity was also notable, with QV Investors Inc. selling a large number of shares of Centene Co. and Swedbank AB also selling off some shares. Despite the ups and downs, Centene made a charitable contribution, with Oklahoma Complete Health donating $75,000 to the Foster Care Association of Oklahoma. Additionally, Peach State Health Plan and the Centene Foundation announced a $100,000 donation to support hurricane relief efforts in Georgia. Overall, the stock price of Centene (NYSE:CNC) experienced fluctuations, setting a new 12-month low and seeing gaps down, but also receiving a rating increase to Strong-Buy at StockNews.com.

Centene Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely following Centene Corp and have provided bullish coverage on the company. In their research reports, such as “Centene Corporation: Medicaid Managed Care Expansion and Optimization! – Major Drivers” and “Centene Corporation: Leveraging Dual Eligibles in Medicare and Medicaid & Other Major Drivers”, analysts highlighted the company’s encouraging financial performance in the first quarter of 2024. Centene Corp exceeded expected adjusted earnings per share (EPS) at $2.26, leading to an upward revision in their full-year 2024 forecast to over $6.80 per share. Despite showing solid progress and operational efficiency, analysts also noted ongoing challenges that the company faces.

A look at Centene Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation’s long-term outlook appears positive, as indicated by its Smartkarma Smart Scores. With high scores in Growth, Resilience, and Momentum, the company is well-positioned for future success. Centene’s focus on expanding its health plans in multiple states and offering specialty services like behavioral health shows a commitment to diversification and innovation in the managed care industry.

While Centene scores low in the Dividend category, its strong performance in other areas suggests that investors may still find value in this healthcare company. Overall, Centene Corporation’s Smart Scores reflect a company with a solid foundation and promising prospects for continued growth and success in the long run.

Summary: Centene Corporation is a multi-line managed care organization that provides Medicaid and Medicaid-related programs. The Company has health plans in several states. The Company also provides specialty services, including behavioral health, nurse triage, and treatment compliance.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma